Skip to main content
Top

2013 | OriginalPaper | Hoofdstuk

47. Peripheral Arterial Disease

Auteurs : Giovina Lara Bomba, MD, Jonathan L. Halperin, MD

Gepubliceerd in: Essential Cardiology

Uitgeverij: Springer New York

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Atherosclerotic peripheral arterial disease (PAD) refers to a range of non-coronary arterial vascular syndromes with progressive stenosis, occlusion, or aneurysmal dilation, most commonly affecting the lower extremity. Lower extremity PAD involves occlusive disease of the aorta, iliac, femoral, and more distal arteries. Patients with PAD typically carry a substantial burden of systemic atherosclerotic disease. Like other manifestations of atherosclerosis, the prevalence of PAD is related to hyperlipidemia, diabetes mellitus, hypertension, tobacco smoking, age, gender, and heredity. Clinical manifestations associated with lower extremity PAD include decrements in functional capacity and quality of life, intermittent claudication, and possibly limb loss. In addition, patients with PAD face an increased risk of vascular events including myocardial infarction (MI), stroke, and mortality.
The principles of management for patients with PAD involve measures directed at protecting affected tissues, preserving functional capacity, avoiding disease progression and arterial thrombosis, restoring blood flow, and preventing mortality. Treatment includes local measures, risk factor modification, drug therapy for claudication, and antithrombotic agents. If symptoms persist with conservative therapy, more invasive measures can be taken including atherectomy, balloon angioplasty, stenting, and surgery to overcome arterial obstruction and improve clinical outcomes.
Literatuur
1.
go back to reference Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: The Framingham Study. J Am Geriatr Soc. 1985;33:13.PubMed Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: The Framingham Study. J Am Geriatr Soc. 1985;33:13.PubMed
2.
go back to reference Kannel WB et al. Intermittent claudication: incidence in the Framingham study. Circulation. 1970;41:875–83.PubMedCrossRef Kannel WB et al. Intermittent claudication: incidence in the Framingham study. Circulation. 1970;41:875–83.PubMedCrossRef
3.
go back to reference Criqui MH, Froner A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985;71:510–5.PubMedCrossRef Criqui MH, Froner A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985;71:510–5.PubMedCrossRef
4.
go back to reference Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease: The San Luis Valley Diabetes Study. Circulation. 1995;91:1472–9.PubMedCrossRef Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease: The San Luis Valley Diabetes Study. Circulation. 1995;91:1472–9.PubMedCrossRef
5.
go back to reference Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–24.PubMedCrossRef Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–24.PubMedCrossRef
6.
go back to reference Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300:197–208.PubMedCrossRef Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300:197–208.PubMedCrossRef
7.
go back to reference Dieh C, Allenberg JR, Pittrow D, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120:2053–61.CrossRef Dieh C, Allenberg JR, Pittrow D, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120:2053–61.CrossRef
8.
go back to reference Fowkes FG, Housley E, Riemersma RA, et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol. 1992;135:331–40.PubMed Fowkes FG, Housley E, Riemersma RA, et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol. 1992;135:331–40.PubMed
9.
go back to reference Sanderson KJ, van Rij AM, Wade CR, et al. Lipid peroxidation of circulating low density lipoproteins with age, smoking and in peripheral vascular disease. Atherosclerosis. 1995;118:45–51.PubMedCrossRef Sanderson KJ, van Rij AM, Wade CR, et al. Lipid peroxidation of circulating low density lipoproteins with age, smoking and in peripheral vascular disease. Atherosclerosis. 1995;118:45–51.PubMedCrossRef
10.
go back to reference Harris LM, Armstrong D, Browne R, et al. Premature peripheral vascular disease: clinical profile and abnormal lipid peroxidation. Cardiovasc Surg. 1998;6:188–93.PubMedCrossRef Harris LM, Armstrong D, Browne R, et al. Premature peripheral vascular disease: clinical profile and abnormal lipid peroxidation. Cardiovasc Surg. 1998;6:188–93.PubMedCrossRef
11.
go back to reference Katsilambros NL, Tsapogas PC, Arvanitis MP, et al. Risk factors for lower extremity arterial disease in non-insulin-dependent diabetic persons. Diabet Med. 1996;13:243–6.PubMedCrossRef Katsilambros NL, Tsapogas PC, Arvanitis MP, et al. Risk factors for lower extremity arterial disease in non-insulin-dependent diabetic persons. Diabet Med. 1996;13:243–6.PubMedCrossRef
12.
go back to reference Murabito JM, Evans JC, Nieto K, et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J. 2002;143:961–5.PubMedCrossRef Murabito JM, Evans JC, Nieto K, et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J. 2002;143:961–5.PubMedCrossRef
13.
go back to reference Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand. 1987;221:253–60.PubMedCrossRef Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand. 1987;221:253–60.PubMedCrossRef
14.
go back to reference Lassila R, Lepantalo M. Cigarette smoking and the outcome after lower limb arterial surgery. Acta Chir Scand. 1988;154:635–40.PubMed Lassila R, Lepantalo M. Cigarette smoking and the outcome after lower limb arterial surgery. Acta Chir Scand. 1988;154:635–40.PubMed
15.
go back to reference McDermott MM, Criqui MH, Ferrucci L, Guralnik JM, Tian L, Liu K, et al. Obesity, weight change, and functional decline in peripheral arterial disease. J Vasc Surg. 2006;43:1198–204.PubMedCrossRef McDermott MM, Criqui MH, Ferrucci L, Guralnik JM, Tian L, Liu K, et al. Obesity, weight change, and functional decline in peripheral arterial disease. J Vasc Surg. 2006;43:1198–204.PubMedCrossRef
16.
go back to reference McDermott MM, Hoff F, Ferrucci L, Pearce WH, Guralnik JM, Tian L, et al. Lower extremity ischemia, calf skeletal muscle characteristics, and functional impairment in peripheral arterial disease. J Am Geriatr Soc. 2007;55:400–6.PubMedCrossRef McDermott MM, Hoff F, Ferrucci L, Pearce WH, Guralnik JM, Tian L, et al. Lower extremity ischemia, calf skeletal muscle characteristics, and functional impairment in peripheral arterial disease. J Am Geriatr Soc. 2007;55:400–6.PubMedCrossRef
17.
go back to reference Criqui M, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients ith peripheral arterial disease. N Engl J Med. 1992;328:381–6.CrossRef Criqui M, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients ith peripheral arterial disease. N Engl J Med. 1992;328:381–6.CrossRef
18.
go back to reference Muluk SC, Muluk VS, Kelley ME, et al. Outcome events in patients with claudication: a 15-year study in 2777 patients. J Vasc Surg. 2001;33:251–7.PubMedCrossRef Muluk SC, Muluk VS, Kelley ME, et al. Outcome events in patients with claudication: a 15-year study in 2777 patients. J Vasc Surg. 2001;33:251–7.PubMedCrossRef
20.
go back to reference McDermott MM, Greenland P, Liu K, et al. The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med. 2002;136:873–83.PubMedCrossRef McDermott MM, Greenland P, Liu K, et al. The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med. 2002;136:873–83.PubMedCrossRef
21.
go back to reference Abola MT, Bhatt DL, Duval S, Cacoub PP, Baumgartner I, Keo H, et al. Fate of individuals with ischemic amputations in the REACH registry: three-year cardiovascular and limb-related outcomes. Atherosclerosis. 2012;221:527–35.PubMedCrossRef Abola MT, Bhatt DL, Duval S, Cacoub PP, Baumgartner I, Keo H, et al. Fate of individuals with ischemic amputations in the REACH registry: three-year cardiovascular and limb-related outcomes. Atherosclerosis. 2012;221:527–35.PubMedCrossRef
22.
go back to reference Fayad ZA et al. In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta. Circulation. 2000;101:2503–9.PubMedCrossRef Fayad ZA et al. In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta. Circulation. 2000;101:2503–9.PubMedCrossRef
23.
go back to reference Montgomery DH, Ververis JJ, McGorisk G, Frohwein S, Martin RP, Taylor WR. Natural history of severe atheromatous disease of the thoracic aorta: a transesophageal echocardiographic study. J Am Coll Cardiol. 1996;27:95–101.PubMedCrossRef Montgomery DH, Ververis JJ, McGorisk G, Frohwein S, Martin RP, Taylor WR. Natural history of severe atheromatous disease of the thoracic aorta: a transesophageal echocardiographic study. J Am Coll Cardiol. 1996;27:95–101.PubMedCrossRef
24.
go back to reference Bartholomew JR, Olin JW. Atheromatous embolization. In: Young JR, Olin JW, Bartholomew JR, editors. Peripheral vascular diseases. 2nd ed. St. Louis: C.V. Mosby Company; 1996. Bartholomew JR, Olin JW. Atheromatous embolization. In: Young JR, Olin JW, Bartholomew JR, editors. Peripheral vascular diseases. 2nd ed. St. Louis: C.V. Mosby Company; 1996.
26.
27.
go back to reference Adar R, Papa MZ, Halpern Z, Mozes M, Shoshan S, Sofer B, et al. Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med. 1983;308:1113–6.PubMedCrossRef Adar R, Papa MZ, Halpern Z, Mozes M, Shoshan S, Sofer B, et al. Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med. 1983;308:1113–6.PubMedCrossRef
28.
go back to reference Halperin JL. Noninvasive vascular laboratory evaluation: applications for laser angioplasty. In: Sanborn TA, editor. Laser angioplasty. New York: AR Liss; 1989. Halperin JL. Noninvasive vascular laboratory evaluation: applications for laser angioplasty. In: Sanborn TA, editor. Laser angioplasty. New York: AR Liss; 1989.
29.
go back to reference Owen RS, Carpenter JP, Baum RA, et al. Magnetic resonance imaging of angiographically occult runoff vessels in peripheral arterial occlusive disease. N Engl J Med. 1992;326:1577–81.PubMedCrossRef Owen RS, Carpenter JP, Baum RA, et al. Magnetic resonance imaging of angiographically occult runoff vessels in peripheral arterial occlusive disease. N Engl J Med. 1992;326:1577–81.PubMedCrossRef
30.
go back to reference Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1998;81:333–5.PubMedCrossRef Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1998;81:333–5.PubMedCrossRef
31.
go back to reference Regensteiner JG, Hiatt WR. Current medical therapies for patients with peripheral arterial disease: a critical review. Am J Med. 2002;112:49–57.PubMedCrossRef Regensteiner JG, Hiatt WR. Current medical therapies for patients with peripheral arterial disease: a critical review. Am J Med. 2002;112:49–57.PubMedCrossRef
32.
go back to reference Mondillo S, Ballo P, Barbati R, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med. 2003;114:359–64.PubMedCrossRef Mondillo S, Ballo P, Barbati R, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med. 2003;114:359–64.PubMedCrossRef
33.
go back to reference Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRef Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRef
34.
go back to reference UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837–53.CrossRef UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837–53.CrossRef
35.
go back to reference Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755–62.PubMedCrossRef Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755–62.PubMedCrossRef
36.
go back to reference Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–53.PubMedCrossRef Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-­converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–53.PubMedCrossRef
37.
go back to reference Law M, Tang JL. An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med. 1995;155:1933–41.PubMedCrossRef Law M, Tang JL. An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med. 1995;155:1933–41.PubMedCrossRef
38.
go back to reference Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685–91.PubMedCrossRef Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685–91.PubMedCrossRef
39.
go back to reference Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DJ, Reynolds MR, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation. 2012;125:130–9.PubMedCrossRef Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DJ, Reynolds MR, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation. 2012;125:130–9.PubMedCrossRef
40.
go back to reference PACK Claudication Substudy Investigators. Randomized placebo-controlled, double-blind trial of ketanserin in claudicants: changes in claudication distance and ankle systolic pressure. Circulation. 1989;80:1544–8.CrossRef PACK Claudication Substudy Investigators. Randomized placebo-controlled, double-blind trial of ketanserin in claudicants: changes in claudication distance and ankle systolic pressure. Circulation. 1989;80:1544–8.CrossRef
41.
go back to reference Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med. 1999;159:337–45.PubMedCrossRef Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med. 1999;159:337–45.PubMedCrossRef
42.
go back to reference Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523–30.PubMedCrossRef Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523–30.PubMedCrossRef
43.
go back to reference Dawson DL, Cutler BS, Meissner MH, et al. Cilostazol has beneficial effects in treatment of intermittent claudication. Circulation. 1998;98:678–86.PubMedCrossRef Dawson DL, Cutler BS, Meissner MH, et al. Cilostazol has beneficial effects in treatment of intermittent claudication. Circulation. 1998;98:678–86.PubMedCrossRef
44.
go back to reference Hiatt WR, Nawaz D, Brass EP. Carnitine metabolism during exercise in patients with peripheral arterial disease. J Appl Physiol. 1987;74:236–40. Hiatt WR, Nawaz D, Brass EP. Carnitine metabolism during exercise in patients with peripheral arterial disease. J Appl Physiol. 1987;74:236–40.
45.
go back to reference Brevetti G, Chiariello M, Ferulano G, et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation. 1988;77:767–73.PubMedCrossRef Brevetti G, Chiariello M, Ferulano G, et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation. 1988;77:767–73.PubMedCrossRef
46.
go back to reference The ICAI (Ischemia Cronica degli Arti Inferiori) Study Group. Prostanoids for chronic critical limb ischemia: a randomized, controlled, open-label trial with prostaglandin E1. Ann Intern Med. 1999;130:412–21.CrossRef The ICAI (Ischemia Cronica degli Arti Inferiori) Study Group. Prostanoids for chronic critical limb ischemia: a randomized, controlled, open-label trial with prostaglandin E1. Ann Intern Med. 1999;130:412–21.CrossRef
47.
go back to reference Maxwell AJ, Anderson BE, Cooke JP. Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar. Vasc Med. 2000;5:11–9.PubMed Maxwell AJ, Anderson BE, Cooke JP. Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar. Vasc Med. 2000;5:11–9.PubMed
48.
go back to reference Hiatt WR, Klepack E, Nehler M, et al. Effects of avasimide in claudicants with peripheral arterial disease. J Am Coll Cardiol. 2003;41(Suppl A):304A.CrossRef Hiatt WR, Klepack E, Nehler M, et al. Effects of avasimide in claudicants with peripheral arterial disease. J Am Coll Cardiol. 2003;41(Suppl A):304A.CrossRef
49.
go back to reference Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet. 2002;359:2053–8.PubMedCrossRef Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet. 2002;359:2053–8.PubMedCrossRef
50.
go back to reference Rajagopalan S, Mohler III ER, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003;108:1933–8.PubMedCrossRef Rajagopalan S, Mohler III ER, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003;108:1933–8.PubMedCrossRef
51.
go back to reference Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002;360:427–35.PubMedCrossRef Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002;360:427–35.PubMedCrossRef
52.
go back to reference Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994;308:81–101.CrossRef Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994;308:81–101.CrossRef
53.
go back to reference Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J. 2002;324:71–86.CrossRef Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J. 2002;324:71–86.CrossRef
54.
go back to reference CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329–39.CrossRef CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329–39.CrossRef
55.
go back to reference Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med. 2007;261:276–81.PubMedCrossRef Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med. 2007;261:276–81.PubMedCrossRef
56.
go back to reference Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Br Med J. 2008;337:a1840.CrossRef Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Br Med J. 2008;337:a1840.CrossRef
57.
go back to reference Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841–8.PubMedCrossRef Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841–8.PubMedCrossRef
58.
go back to reference Cacoub PP, Bhatt DL, Steg PG, et al. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009;301:1909–19. Cacoub PP, Bhatt DL, Steg PG, et al. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009;301:1909–19.
59.
go back to reference Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982–8.PubMedCrossRef Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982–8.PubMedCrossRef
60.
go back to reference Anand S, Yusuf S, Xie C, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357:217–27.PubMedCrossRef Anand S, Yusuf S, Xie C, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357:217–27.PubMedCrossRef
61.
go back to reference Watson HR, Bergqvist D. Antithrombotic agents for peripheral transluminal angioplasty: a review of the studies, methods, and evidence for use. Eur J Vasc Endovasc Surg. 2000;19:445–50.PubMedCrossRef Watson HR, Bergqvist D. Antithrombotic agents for peripheral transluminal angioplasty: a review of the studies, methods, and evidence for use. Eur J Vasc Endovasc Surg. 2000;19:445–50.PubMedCrossRef
62.
go back to reference Girolami B, Bernardi E, Prins MH, ten Cate JW, Prandoni P, Simioni P, et al. Antiplatelet therapy and other interventions after revascularization procedures in patients with peripheral arterial disease: a meta-analysis. Eur J Vasc Endovasc Surg. 2000;19:370–80.PubMedCrossRef Girolami B, Bernardi E, Prins MH, ten Cate JW, Prandoni P, Simioni P, et al. Antiplatelet therapy and other interventions after revascularization procedures in patients with peripheral arterial disease: a meta-analysis. Eur J Vasc Endovasc Surg. 2000;19:370–80.PubMedCrossRef
63.
go back to reference Jahnke T, Link J, Muller-Hulsbeck S, Grimm J, Heller M, Brossman J. Treatment of infrapopliteal occlusive disease by high-speed rotational atherectomy: initial and mid-term results. J Vasc Interv Radiol. 2001;12:221–6.PubMedCrossRef Jahnke T, Link J, Muller-Hulsbeck S, Grimm J, Heller M, Brossman J. Treatment of infrapopliteal occlusive disease by high-speed rotational atherectomy: initial and mid-term results. J Vasc Interv Radiol. 2001;12:221–6.PubMedCrossRef
64.
go back to reference Dormandy JA et al. Endovascular procedures for intermittent claudication. J Vasc Surg. 2000;31:S97–113.CrossRef Dormandy JA et al. Endovascular procedures for intermittent claudication. J Vasc Surg. 2000;31:S97–113.CrossRef
65.
go back to reference Gray BH, Sullivan TM, Childs MB, Young JR, Olin JW. High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty. J Vasc Surg. 1997;25:74–83.PubMedCrossRef Gray BH, Sullivan TM, Childs MB, Young JR, Olin JW. High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty. J Vasc Surg. 1997;25:74–83.PubMedCrossRef
66.
go back to reference Krueger K, Landwehr P, Bendel M, Nolte M, Stuetzeer H, Bogartz R, et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology. 2002;224:519–28.PubMedCrossRef Krueger K, Landwehr P, Bendel M, Nolte M, Stuetzeer H, Bogartz R, et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology. 2002;224:519–28.PubMedCrossRef
67.
go back to reference Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease. Six-month results Circulation. 2002;106:1505–9. Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease. Six-month results Circulation. 2002;106:1505–9.
68.
go back to reference Ouriel K, Veith FJ, Sasahara AA. Comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med. 1998;338:1105–11.PubMedCrossRef Ouriel K, Veith FJ, Sasahara AA. Comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med. 1998;338:1105–11.PubMedCrossRef
69.
go back to reference Weaver FA, Comerota AJ, Youngblood M, Froehlich J, Hosking JD, Papanicolaou G. Surgical revascularization versus thrombolysis for nonembolic lower extremity native artery occlusions: results of a prospective randomized trial. The STILE Investigators. Survey versus Thrombolysis for Ischemia of the Lower Extremity. J Vasc Surg. 1996;24:513–21.PubMedCrossRef Weaver FA, Comerota AJ, Youngblood M, Froehlich J, Hosking JD, Papanicolaou G. Surgical revascularization versus thrombolysis for nonembolic lower extremity native artery occlusions: results of a prospective randomized trial. The STILE Investigators. Survey versus Thrombolysis for Ischemia of the Lower Extremity. J Vasc Surg. 1996;24:513–21.PubMedCrossRef
go back to reference Abola MT, Bhatt DL, Duval S, Cacoub PP, Baumgartner I, Keo H, et al. Fate of individuals with ischemic amputations in the REACH registry: Three-year cardiovascular and limb-related outcomes. Atherosclerosis. 2012;221:527–35.PubMedCrossRef Abola MT, Bhatt DL, Duval S, Cacoub PP, Baumgartner I, Keo H, et al. Fate of individuals with ischemic amputations in the REACH registry: Three-year cardiovascular and limb-related outcomes. Atherosclerosis. 2012;221:527–35.PubMedCrossRef
go back to reference Dieh C, Allenberg JR, Pittrow D, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120:2053–61.CrossRef Dieh C, Allenberg JR, Pittrow D, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120:2053–61.CrossRef
go back to reference Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300:197–208.PubMedCrossRef Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300:197–208.PubMedCrossRef
go back to reference Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WRC, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr., White CJ, White J, White RA. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to develop guidelines for the management of patients with peripheral arterial disease [Lower extremity, renal, mesenteric, and abdominal aortic]). J Am Coll Cardiol. 2006;47:1239–312. Summary available at www.acc.org/clinical/guidelines/pad/summary.pdf Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WRC, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr., White CJ, White J, White RA. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to develop guidelines for the management of patients with peripheral arterial disease [Lower extremity, renal, mesenteric, and abdominal aortic]). J Am Coll Cardiol. 2006;47:1239–312. Summary available at www.​acc.​org/​clinical/​guidelines/​pad/​summary.​pdf
go back to reference McDermott MM, Hoff F, Ferrucci L, Pearce WH, Guralnik JM, Tian L, et al. Lower extremity ischemia, calf skeletal muscle characteristics, and functional impairment in peripheral arterial disease. J Am Geriatr Soc. 2007;55:400–6.PubMedCrossRef McDermott MM, Hoff F, Ferrucci L, Pearce WH, Guralnik JM, Tian L, et al. Lower extremity ischemia, calf skeletal muscle characteristics, and functional impairment in peripheral arterial disease. J Am Geriatr Soc. 2007;55:400–6.PubMedCrossRef
go back to reference Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DJ, Reynolds MR, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation. 2012;125:130–9.PubMedCrossRef Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DJ, Reynolds MR, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation. 2012;125:130–9.PubMedCrossRef
go back to reference Rooke TW, Hirsch AT, Misra S, Sidawy A, Beckman JA, Findeiss L, Golzarian J, Gornik HL, Halperin JL, Jaff MR, Moneta GL, Olin JW, Stanley JC, White J, White CJ, Zierler RE. 2010 ACCF/AHA focused update of the guidelines for management of patients with peripheral arterial disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58:2020–45. http://content.onlinejacc.org/cgi/content/full/j.jacc.2011.08.023v1 Rooke TW, Hirsch AT, Misra S, Sidawy A, Beckman JA, Findeiss L, Golzarian J, Gornik HL, Halperin JL, Jaff MR, Moneta GL, Olin JW, Stanley JC, White J, White CJ, Zierler RE. 2010 ACCF/AHA focused update of the guidelines for management of patients with peripheral arterial disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58:2020–45. http://​content.​onlinejacc.​org/​cgi/​content/​full/​j.​jacc.​2011.​08.​023v1
Metagegevens
Titel
Peripheral Arterial Disease
Auteurs
Giovina Lara Bomba, MD
Jonathan L. Halperin, MD
Copyright
2013
Uitgeverij
Springer New York
DOI
https://doi.org/10.1007/978-1-4614-6705-2_47